NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) said that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center or BIDMC to support the development of a preventive vaccine candidate for COVID-19.
The companies have commenced preclinical testing of multiple vaccine prospects, with the aim to identify by the end of the month a COVID-19 vaccine candidate for clinical trials.
Janssen is optimistic that, in collaboration with multiple global strategic partners, it can initiate a Phase 1 clinical study of a potential vaccine candidate by the end of the year.
In addition, Janssen is preparing to upscale production and manufacturing capacities to levels required to meet global public health vaccination needs.
Copyright RTT News/dpa-AFX
© 2020 AFX News
